Dostarlimab

Brand names: Jemperli · Active ingredient: Dostarlimab

In short: JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). JEMPERLI, as a single agent, is indicated for the treatment of adult patients with mismatch r

Forms & strengthsInjection: 500 mg/10 mL (50 mg/mL) clear to slightly opalescent, colorless to yellow solution in a single-dose vial for intravenous infusion after dilution.
LabelGlaxoSmithKline LLC
Label updatedOct 23, 2026

What is Dostarlimab used for?

JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).

JEMPERLI, as a single agent, is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA‑authorized test, that has progressed on or following prior treatment with a platinum‑containing regimen in any setting and are not candidates for curative surgery or radiation .

JEMPERLI, as a single agent, is indicated for the treatment of adult patients with Stage II/III, locally advanced rectal cancer (LARC) that is microsatellite instability‑high (MSI‑H) or dMMR, as determined by an FDA‑authorized test for solid tumors . This indication is approved under accelerated approval based on sustained clinical complete response for 12 months . The long-term risk of relapse is unknown, with additional follow-up expected. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options . …

Dostarlimab dosage

Single Agent

Select patients for treatment with JEMPERLI as a single agent based on the presence of MSI-H and/or dMMR in tumor specimens in:

•

recurrent or advanced EC .

•

LARC .

•

recurrent or advanced solid tumors .

Information on FDA‑authorized tests for the detection of MSI‑H/dMMR status is available at https://www.fda.gov/companiondiagnostics.

Because the effect of prior chemotherapy on test results for dMMR in patients with high‑grade gliomas is unclear, it is recommended to test for this marker in the primary tumor specimen obtained prior to initiation of temozolomide chemotherapy in patients with high‑grade gliomas.

The recommended dosage for JEMPERLI is presented in Table 1.

Administer JEMPERLI as a 30-minute intravenous infusion .

EC = Endometrial Cancer; dMMR = Mismatch Repair Deficient; MSI‑H = Microsatellite Instability‑High.

a Refer to the Prescribing Information for the agents administered in combination with JEMPERLI, as appropriate.

Indication | Recommended Dosage | Duration/Timing of Treatment

Combination Therapy

Adults with primary advanced or recurrent EC | 500 mg JEMPERLI every 3 weeks for 6 cycles in combination with carboplatin and paclitaxela followed by 1,000 mg JEMPERLI as monotherapy every 6 weeks for all cycles thereafter.

Administer JEMPERLI prior to carboplatin and paclitaxel when given on the same day. | Until disease progression, unacceptable toxicity, or up to 3 years

Monotherapy

Adults with MSI‑H/dMMR locally advanced rectal cancer | 500 mg JEMPERLI every 3 weeks for 9 cycles. | Until disease progression, unacceptable toxicity, or 9 cycles.

Adults with dMMR recurrent or advanced EC and

dMMR recurrent or advanced solid tumors | 500 mg JEMPERLI every 3 weeks for 4 cycles followed by 1,000 mg JEMPERLI every 6 weeks for all cycles thereafter. | Until disease progression or unacceptable toxicity

No dose reductions of JEMPERLI are recommended. In general, withhold JEMPERLI for severe (Grade 3) immune‑mediated adverse reactions. Permanently discontinue JEMPERLI for life‑threatening (Grade 4) immune‑mediated adverse reactions, recurrent severe (Grade 3) immune‑mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating steroids.

Dosage modifications for JEMPERLI for adverse reactions that require management different from these general guidelines are summarized in Table 2.

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; DRESS = Drug Rash with Eosinophilia and Systemic Symptoms; SJS = Stevens‑Johnson Syndrome; TEN = Toxic Epidermal Necrolysis; ULN = Upper Limit of Normal.

a Based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0. …

How to take Dostarlimab — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Immune-Mediated Adverse Reactions

Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid or other treatment and interruption or discontinuation of JEMPERLI. These reactions may include:

•Pneumonitis: Advise patients to contact their healthcare provider immediately for new or worsening cough, chest pain, or shortness of breath .

•Colitis: Advise patients to contact their healthcare provider immediately for diarrhea or severe abdominal pain .

•Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, or easy bruising or bleeding .

•Immune-mediated endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, hypophysitis, or type 1 diabetes mellitus .

•Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis . …

Warnings & precautions

Do not take this medicine if: None.

JEMPERLI is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance, and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed in WARNINGS AND PRECAUTIONS may not include all possible severe and fatal immune‑mediated reactions.

Immune-mediated adverse reactions, which can be severe or fatal, can occur in any organ system or tissue. Immune‑mediated adverse reactions can occur at any time after starting a PD-1/PD-L1–blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1–blocking antibodies, they can also manifest after discontinuation of PD-1/PD-L1–blocking antibodies.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD‑1/PD‑L1–blocking antibodies. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function tests at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue JEMPERLI depending on severity . In general, if JEMPERLI requires interruption or discontinuation, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. …

Dostarlimab side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Severe and fatal immune-mediated adverse reactions

•Infusion-related reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety described in WARNINGS AND PRECAUTIONS reflects exposure to JEMPERLI as a single agent in 759 patients in two non‑randomized, single-arm, open‑label trials; the multicohort GARNET trial (n = 605, patients with advanced or recurrent EC or other solid tumors) and the AZUR-1 trial (n = 154, patients with LARC). The data described in WARNINGS AND PRECAUTIONS also reflects exposure to JEMPERLI in combination with carboplatin and paclitaxel in 241 patients with primary advanced or recurrent EC in the randomized, double-blind active‑control RUBY trial.

Primary Advanced or Recurrent Endometrial Cancer: JEMPERLI in Combination with Carboplatin and Paclitaxel

The safety of JEMPERLI in patients with primary advanced or recurrent EC was evaluated in RUBY . Patients received JEMPERLI 500 mg (n = 241) or placebo (n = 246) in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles followed by JEMPERLI 1,000 mg or placebo every 6 weeks until disease progression or unacceptable toxicity. …

About this medicine

Dostarlimab-gxly is a programmed death receptor-1 (PD-1)–blocking IgG4 humanized monoclonal antibody. Dostarlimab‑gxly is produced in Chinese hamster ovary cells and has a calculated molecular weight of about 144 kDa.

JEMPERLI (dostarlimab-gxly) injection is a sterile, clear to slightly opalescent, colorless to yellow solution essentially free from visible particles. It is supplied as single-dose vials.

Each vial contains 500 mg of JEMPERLI in 10 mL of solution with a pH of 6. Each mL of solution contains 50 mg of dostarlimab-gxly, citric acid monohydrate (0.48 mg), L-arginine hydrochloride (21.07 mg), polysorbate 80 (0.2 mg), sodium chloride (1.81 mg), trisodium citrate dihydrate (6.68 mg), and Water for Injection, USP.

How it works: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 095eab9f-545a-4f12-bfb7-19477fb901a5. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate